METABOLOMICS TECHNOLOGY APPLIED TO DIABETES RESEARCH
RESEARCH TRIANGLE PARK, N.C. (November 30, 2010) — Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of “Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting” in PLoS ONE.
Data from Metabolon’s non-targeted biochemical profiling platform was combined with data collected from targeted metabolomics platforms to identify metabolic signatures that are associated with Type 2 diabetes. The proof of concept study illustrates the value of using metabolomics to identify biochemical pathways affected by Type 2 diabetes. The authors show that functional metabolomics can contribute to the development of a more sophisticated classification of the disease and lead to optimized diagnosis and treatment options. Copies of the paper can be accessed from PLoS ONE: http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013953.
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.